Articles

A life-sciences columnist with a twist: Getting to know Randy

Though he's been with us for more than a decade, we thought we'd introduce (or, for many of you, re-introduce) one of our two regular columnists
Written byJeffrey Bouley
| 3 min read

Randall C Willis is a biochemist by training, with a B.Sc. focused on molecular biology and—wait a minute; that’s not right. I mean, it is right—accurate, that is—but that’s no way to start this profile of one of our two esteemed columnists at DDNews (following up the one we did for Peter Kissinger last month).

If you read the “Out of order” column with any regularity (appearing in this issue and alternating issues with Pete’s column), you must have picked up on the fact that Mr. Willis has eclectic tastes and is not one to shy from using wit as he tackles serious issues of the life sciences, pharma and biotech. He likes to say “attempts at wit” but I’d argue he hits the mark far more often than not.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 13 - Issue 11 | November 2017

November 2017

November 2017 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue